双特异性抗体在多发性骨髓瘤中的演进 The evolution of bispecific antibodies in multiple myeloma. PubMed 2026/02/01 发表Chin Clin OncolQ3 · IF 2.7(JCR 2025) 靶点:CD20靶点:CD38靶点:BCMA技术:双特异性抗体多发性骨髓瘤B细胞淋巴瘤淋巴瘤
肾脏病学趋势:从虚无主义到抗体介导排斥反应的靶向治疗 Trends in Nephrology: From nihilism to targeted treatment of antibody-mediated rejection. PubMed 2026/01/24 发表Nephrol Dial TransplantQ1 · IF 8.3(JCR 2025) 靶点:CD19靶点:CD20靶点:CD38技术:NK 细胞技术:双特异性抗体多发性骨髓瘤
2023 年美国 FDA 批准的治疗性抗体的结构与功能 Structure and function of therapeutic antibodies approved by the US FDA in 2023. PubMed 2024/03/19 发表Antib TherQ2 · IF 4.8(JCR 2025) 人群:儿童靶点:CD20靶点:BCMA靶点:GPRC5D技术:双特异性抗体弥漫大B细胞淋巴瘤多发性骨髓瘤淋巴瘤